Bone morphogenetic protein 6-induced interleukin-1β expression in macrophages requires PU.1/Smad1 interaction.

Mol Immunol

Section of Urologic Oncology and the Dean and Betty Gallo Prostate Cancer Center, The Cancer Institute of New Jersey, Robert Wood Johnson Medical School, 195 Little Albany Street #4560, New Brunswick, NJ 08903, United States.

Published: July 2011

AI Article Synopsis

  • Interleukin 1β (IL-1β) is a cytokine involved in inflammation, produced by activated macrophages and monocytes.
  • Bone morphogenetic protein-6 (BMP-6) plays a role in increasing IL-1β expression, utilizing specific receptors (ALK3, BMPRII) and the signaling protein Smad1 in macrophages.
  • The study uncovers that both Smad and non-Smad pathways need to interact for IL-1β upregulation, highlighting the importance of the transcription factor PU.1 in this process.

Article Abstract

Interleukin 1β (IL-1β) is a pro-inflammatory cytokine secreted by activated macrophages and monocytes. Previously, we have reported that bone morphogenetic protein-6 (BMP-6) induces inducible nitric oxide synthase (iNOS) expression via IL-1β in macrophages. In the present study, we demonstrate that BMP-6 increases IL-1β expression in macrophages via the receptors ALK3 and BMPRII as well as the downstream signaling protein Smad1. Surprisingly though, inhibition of the ERK and JNK non-Smad pathways also completely blocked the induction of IL-1β by BMP-6 in macrophages. Further analysis revealed that a physical interaction between the transcription factor PU.1 and Smad 1 is necessary for the upregulation of IL-1β expression by BMP-6 in macrophages. Taken together, these results demonstrate that BMP-6-induced IL-1β expression in macrophages is mediated via a cross-talk between the Smad and the non-Smad pathways through Smad1 and PU.1.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.molimm.2011.04.019DOI Listing

Publication Analysis

Top Keywords

expression macrophages
12
il-1β expression
12
bone morphogenetic
8
non-smad pathways
8
bmp-6 macrophages
8
macrophages
7
il-1β
6
expression
5
morphogenetic protein
4
protein 6-induced
4

Similar Publications

Background: Lung adenocarcinoma is one of the most common malignant tumors worldwide. Its complex molecular mechanisms and high tumor heterogeneity pose significant challenges for clinical treatment. The manganese ion metabolism family plays a crucial role in various biological processes, and the abnormal expression of the NUDT3 gene in multiple cancers has drawn considerable attention.

View Article and Find Full Text PDF

Environmental factors play a crucial role in bacterial virulence. During transmission, in a non-host environment bacteria are exposed to various environmental stress which could alter bacterial physiology and virulence. N.

View Article and Find Full Text PDF

Unlocking the potential of : A breakthrough in liver cancer treatment Wnt/β-catenin pathway modulation.

World J Gastroenterol

January 2025

Department of Internal Medicine, Mixed Hospital of Laghouat, Laghouat Faculty of Medicine, Amar Telidji University, Laghouat 03000, Algeria.

Liver cancer remains a significant global health challenge, characterized by high incidence and mortality rates. Despite advancements in medical treatments, the prognosis for liver cancer patients remains poor, highlighting the urgent need for novel therapeutic approaches. Traditional Chinese medicine (TCM), particularly (CB), has shown promise in addressing this need due to its multi-target therapeutic mechanisms.

View Article and Find Full Text PDF

Background: Neoadjuvant, endocrine, and targeted therapies have significantly improved the prognosis of breast cancer (BC). However, due to the high heterogeneity of cancer, some patients cannot benefit from existing treatments. Increasing evidence suggests that amino acids and their metabolites can alter the tumor malignant behavior through reshaping tumor microenvironment and regulation of immune cell function.

View Article and Find Full Text PDF

A novel application perspective of the clinical-used drug verapamil on osteoporosis via targeting .

J Orthop Translat

January 2025

Shanghai Key Laboratory of Orthopedic Implants, Department of Orthopedic Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, People's Republic of China.

Background: RANKL and SCLEROSTIN antibodies have provided a strong effective choice for treating osteoporosis in the past years, which suggested novel molecular target identification and therapeutic strategies development are important for the treatment of osteoporosis. The therapeutic effect of verapamil, a drug previously used for cardiovascular diseases, on diabetes was due to the inhibition of TXNIP expression, which has also been reported as a target in mice osteoporosis. Whether verapamil-inhibited TXNIP expression is related to osteoporosis and how it works on the molecular level is worthy to be explored.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!